Clinical Report: Real-World Analysis of Dapagliflozin in HFrEF Patients in the UK
Overview
This study evaluates the real-world initiation and effects of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) in the UK.
Background
Heart failure with reduced ejection fraction (HFrEF) is a significant health concern, with increasing prevalence and associated morbidity. Optimal management includes guideline-directed medical therapy, including sodium-glucose cotransporter-2 inhibitors (SGLT2i) like dapagliflozin. Understanding real-world outcomes of dapagliflozin use is essential for improving patient care.
Data Highlights
Characteristic
Value
Mean Age
69.3 years
Discontinuation Rate
11.7/100 patient-years
KCCQ-23 Score at Baseline
67.6
KCCQ-23 Score at 12 Months
71.6
Work Impairment at Baseline
31.2%
Work Impairment at 12 Months
16.3%
Key Findings
Mean age of participants was 69.3 years, with 70.0% male and 91.6% White.
The mean interval from HFrEF diagnosis to dapagliflozin initiation was 20.9 months.
Adverse drug reactions accounted for 65.0% of dapagliflozin discontinuations.
Overall KCCQ-23 scores improved from 67.6 to 71.6 over 12 months.
Work impairment decreased from 31.2% at baseline to 16.3% at 12 months.
54.4% of participants were on four treatment pillars at enrolment, increasing to 58.4% at 12 months.
Clinical Implications
The study highlights the importance of monitoring patient adherence and quality of life in those prescribed dapagliflozin for HFrEF. Clinicians should consider optimizing therapy to ensure patients receive all four recommended treatment pillars.
Conclusion
Dapagliflozin demonstrates favorable real-world outcomes in HFrEF management, with low discontinuation rates and improvements in quality of life. Further optimization of therapy is warranted to enhance patient outcomes.
